Traws Pharma, Inc.
TRAW Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.34
KIRA · Stoqly’s AI analyst, in plain words
- Traws Pharma, Inc. had $2.8M of revenue in fiscal 2024, up 1,134.5% on the year before. Over five years, revenue changed +64.6% a year on average.
- Its operating margin was −640.7%, up 62,356.7 pts: of every 100 in sales, about −641 is left after running the business.
- Traws Pharma, Inc. made $9.2M of net profit in fiscal 2024.
- Free cash flow was −$20.8M in fiscal 2024, −744.4% of revenue.
Market cap
$5.4M
P/E
—
Revenue
$2.8M
Net income
$9.2M
Free cash flow
−$20.8M
Operating margin
−640.7%
Traws Pharma, Inc. in 30 seconds · fiscal 2024
Are sales growing?
+1,134.5%
Yes. Sales grew 1,134.5% last year.
Does it make a profit?
328.7%
Yes. It keeps 328.7% of every sale as profit.
Does profit turn into cash?
−744.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Traws Pharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 15, 2026
- Legal name
- Traws Pharma, Inc.
- CIK
- 0001130598
Traws Pharma, Inc. · TRAW
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.2M | $0.2M | $0.2M | $0.2M | $2.8M |
| Revenue growth | −2.2% | 0.0% | 0.0% | 0.0% | 1,134.5% |
| Operating margin | −7,299.1% | −8,684.5% | −8,981.4% | −62,997.3% | −640.7% |
| Net income | −$16.2M | −$19.0M | −$18.9M | −$167M | $9.2M |
| Net margin | −7,151.8% | −8,391.2% | −8,384.1% | −73,682.7% | 328.7% |
| Diluted EPS | −$0.96 | −$0.91 | −$22.57 | −$35.21 | $0.82 |
| Cash | |||||
| Cash from operations | −$19.5M | −$16.3M | −$17.9M | −$29.8M | −$18.2M |
| Capital expenditure | — | — | $0.0M | $3.6M | $2.6M |
| Free cash flow | — | — | −$17.9M | −$33.4M | −$20.8M |
| FCF margin | — | — | −7,940.7% | −14,796.5% | −744.4% |
| Share count change | 45.1% | 24.2% | −96.0% | 84.9% | 439.5% |
| Debt and strength | |||||
| Cash and short-term investments | $55.1M | $38.5M | $20.6M | $21.3M | $3.8M |
| Shareholders' equity | $46.1M | $28.3M | $10.7M | −$31.6M | −$0.6M |
| Current ratio | 9.1x | 4.9x | 2.5x | 2.2x | 0.7x |
| Returns and quality | |||||
| Return on equity | −61.8% | −51.0% | −97.2% | — | — |
| Return on tangible equity | −35.0% | −67.0% | −177.5% | — | — |
| Piotroski F-score | 2 | 2 | 3 | 1 | 3 |
| Altman Z'' | −17.1 | −33.8 | −70.6 | −120.2 | −209.8 |
Insiders bought, 12 months
$1.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Traws Pharma, Inc. · TRAW
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.34 a share, the company is worth $5.4M.
Source: SEC EDGAR XBRL filings (CIK 0001130598). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.